Gina Mauro

FDA Grants Ublituximab/Umbralisib Combo Fast Track Status in CLL

October 21st 2020

The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

Meet the New Chief: McCloskey Takes Helm at John Theurer Cancer Center’s Leukemia Division

October 15th 2020

As James K. McCloskey II, MD, begins the next chapter of his career as chief of the Division of Leukemia at John Theurer Cancer Center at Hackensack University Medical Center.

Mobocertinib Continues to Show Clinical Activity in EGFR Exon 20–Mutant NSCLC

October 5th 2020

Mobocertinib elicited a 43% objective response rate and an 86% disease control rate in select patients with non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Increased Lanreotride Autogel Dosing Shows Encouraging Antitumor Activity in Progressive Pancreatic, Midguts NETs

October 3rd 2020

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

Telotristat/Lutathera Combo Could Improve Outcomes in Well-Differentiated NETs

October 2nd 2020

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

FDA Approves Nivolumab/Ipilimumab for Frontline Unresectable Malignant Pleural Mesothelioma

October 2nd 2020

The FDA has approved nivolumab (Opdivo) at 360 mg every 3 weeks plus ipilimumab (Yervoy) at 1 mg/kg every 6 weeks for the frontline treatment of adult patients with unresectable malignant pleural mesothelioma.

Regional Lymph Node Macroscopic Metastases in Sarcoma Linked With Poor OS Outcomes

September 30th 2020

The presence of macroscopic metastases in regional lymph nodes is found to be related to poor survival outcomes in patients with sarcoma.

Germline BRCA2 Status, Other Aberrations Independently Linked With Cause-Specific Survival in Prostate Cancer

September 29th 2020

Patients with prostate cancer who harbor germline BRCA2 mutations were found to have significantly higher rates of somatic BRCA loss, somatic RB1 loss, and MYC amplification compared with non-carriers—factors that were independently associated with poorer survival outcomes.

Plinabulin Shows Efficacy in Chemo-Induced Neutropenia Prevention During COVID-19 Era

September 29th 2020

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

Even in COVID-19 World, Children’s Oncology Group Tackles Unmet Needs in Sarcomas

September 28th 2020

R. Lor Randall, MD, highlights the innovative efforts by the COG, ongoing studies in sarcomas, and how the organization is adapting during a world with COVID-19.

AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL

September 23rd 2020

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Camrelizumab/Apatinib Combo Shows Preliminary Activity in Relapsed/Refractory Peripheral T-Cell Lymphoma

September 23rd 2020

The combination of the investigative PD-1 inhibitor camrelizumab plus the antiangiogenic agent apatinib led to early signals of clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma, warranting further study.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

Frontline Ipatasertib/Abiraterone Regimen Shows Superior Radiographic PFS in PTEN-Loss mCRPC

September 20th 2020

Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

September 20th 2020

BLU-945, an investigational precision therapy, elicited robust antitumor activity in multiple preclinical models of triple-mutated EGFR-positive non–small cell lung cancer .

Frontline Lorlatinib Bests Crizotinib in Advanced ALK+ NSCLC

September 20th 2020

First-line treatment with the third-generation ALK TKI lorlatinib significantly improved progression-free survival, and also was associated with higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC

September 19th 2020

Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.

OncLive News Network On Location: ESMO 2020 Day 3

September 19th 2020

OncLive News Network On Location ESMO 2020 Day 2

September 19th 2020